MedTrace Logo

HIV Reservoir Reduction With Interleukin-2

NCT03308786 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-09-28

Study results available
· View outcomes & findings →

Summary

The purpose of this pilot study is to examine the effects of eight 4-day cycles of subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of replication-competent HIV in CD4 cells and on the size of HIV viral reservoir in up to 20 participants with chronically suppressed HIV infection (viral load \<50 copies/mL).

Conditions

  • HIV Infection

Interventions

DRUG

Recombinant Interleukin-2

Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles

Sponsors & Collaborators

  • Case Western Reserve University

    lead OTHER

Principal Investigators

  • Benigno Rodriguez, MD · Case Western Reserve University

  • Michael Lederman, MD · Case Western Reserve University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-08-20
Completion
2020-08-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03308786 on ClinicalTrials.gov